AstraZeneca
AZN
1,073 hedge funds and large institutions have $33.7B invested in AstraZeneca in 2023 Q3 according to their latest regulatory filings, with 100 funds opening new positions, 420 increasing their positions, 316 reducing their positions, and 99 closing their positions.
43% more call options, than puts
Call options by funds: $805M | Put options by funds: $564M
33% more repeat investments, than reductions
Existing positions increased: 420 | Existing positions reduced: 316
1% more first-time investments, than exits
New positions opened: 100 | Existing positions closed: 99
0.13% more ownership
Funds ownership: 15.92% → 16.05% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 15 → 15 (0)
5% less capital invested
Capital invested by funds: $35.3B → $33.7B (-$1.61B)
2% less funds holding
Funds holding: 1,090 → 1,073 (-17)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sanders Capital
West Palm Beach,
Florida
|
+$721M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$184M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$115M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$95.7M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$91.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$488M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$254M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$144M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$128M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$121M |
AZN Hedge Fund Activity: Q3 2023 in Review
1,073 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2023, worth a combined $33.7B — down 4.6% from $35.3B a quarter earlier.
Buyers outnumbered sellers: 100 funds opened new AZN positions and 99 closed out — a net gain of 1 holder — while 420 added to existing stakes and 316 trimmed.
The largest buyer was Sanders Capital, opening a new position worth an estimated $721M. The largest seller was GQG Partners, cutting an estimated $488M.
- 1,073 institutional investors held AstraZeneca (AZN) as of Q3 2023, down from 1,090 in Q2 2023.
- Funds reported $33.7B of AstraZeneca stock for Q3 2023, down 4.6% quarter-over-quarter.
- 100 funds opened new AstraZeneca positions in Q3 2023 and 99 closed out, a net change of +1 holder.
- The largest AstraZeneca buyer in Q3 2023 was Sanders Capital, an estimated $721M added.
- The largest AstraZeneca seller in Q3 2023 was GQG Partners, an estimated $488M sold.
Based on aggregated 13F filings for Q3 2023.